Patents by Inventor Alan Kozikowski

Alan Kozikowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HDAC inhibitors and therapeutic methods using the same
    Patent number: 11739064
    Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: August 29, 2023
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Alan Kozikowski, Irina Gaisina
  • SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS
    Publication number: 20230250054
    Abstract: The present disclosure provides methods, pharmaceutical compositions, and kits comprising histone deacetylase (HD AC) inhibitors of formula I, or a pharmaceutically acceptable salt thereof, wherein R1, R2, L1, L2, m, n, p, X, Y, and Z are as defined in the specification, including methods of increasing the sensitivity of cancer cells to the cytotoxic effects of radiotherapy and/or chemotherapy in a subject.
    Type: Application
    Filed: June 25, 2021
    Publication date: August 10, 2023
    Inventors: Sida SHEN, Alejandro VILLAGRA, Alan KOZIKOWSKI
  • 3-(2-(Aminoethyl)-Indol-4-ol Derivatives, Methods of Preparation Thereof, and the Use as 5-HT2 Receptor Modulators
    Publication number: 20230140635
    Abstract: A compound of Formula I, which possesses 5-HT2A and/or 5-HT2C selective receptor activity, but lacks at lease some of the undesirable characteristics of 5-HT2B-agonist related activities, is disclosed. Methods of preparing said compounds are also described. The compound of Formula I may be useful in the treatment of depression, alcoholism, tobacco and cocaine addiction, inflammation, cluster headache, PTSD, seizure disorders and other CNS disorders.
    Type: Application
    Filed: March 12, 2021
    Publication date: May 4, 2023
    Inventors: Alan Kozikowski, Gideon Shapiro, Werner Tueckmantel, John McCorvy
  • HDAC Inhibitors and Therapeutic Methods Using the Same
    Publication number: 20210139438
    Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed.
    Type: Application
    Filed: November 16, 2020
    Publication date: May 13, 2021
    Inventors: Alan Kozikowski, Irina Gaisina
  • Small molecules inhibitors of RAD51
    Patent number: 10973819
    Abstract: Embodiments concern methods and small molecule compositions for selectively inhibiting RAD51-mediated D-loop formation while preserving RAD51's ability to form nucleoprotein filaments. The selective RAD51 D-loop formation activity inhibitors DNA repair while minimizing replication-associated toxicity in normal tissue.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: April 13, 2021
    Assignee: The University of Chicago
    Inventors: Philip Connell, Wei Lv, Brian Budke, Alan Kozikowski
  • Nrf and HIF activators/HDAC inhibitors and therapeutic methods using the same
    Patent number: 10934255
    Abstract: Compounds that inhibit histone (HDACI) and/or activate Nrf2 and HIF, and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC and/or activation of Nrf2 and HIF provide a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: March 2, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Irina Gaisina, Alan Kozikowski
  • HDAC inhibitors and therapeutic methods using the same
    Patent number: 10836733
    Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: November 17, 2020
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Alan Kozikowski, Irina Gaisina
  • NRF AND HIF ACTIVATORS/HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME
    Publication number: 20200039933
    Abstract: Compounds that inhibit histone (HDACI) and/or activate Nrf2 and HIF, and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC and/or activation of Nrf2 and HIF provide a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.
    Type: Application
    Filed: April 25, 2018
    Publication date: February 6, 2020
    Inventors: Irina Gaisina, Alan Kozikowski
  • Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors
    Patent number: 10456394
    Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: October 29, 2019
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Alan Kozikowski, Sida Shen, Joel Bergman, Irina Gaisina
  • Cyclopropylmethanamines as selective 5-HT(2C) receptor agonists
    Patent number: 10407381
    Abstract: Disclosed are 2-phenyl-cyclopropylmethanamines which are selective 5-HT(2C) receptor agonists and are used in the treatments of diseases and conditions wherein modulation of 5-HT(2C) receptors provides a benefit, such as obesity and psychiatric disorders.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: September 10, 2019
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Alan Kozikowski, Jianjun Cheng
  • TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS
    Publication number: 20190255046
    Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.
    Type: Application
    Filed: February 15, 2017
    Publication date: August 22, 2019
    Applicant: The Board of Trustees of the University of Illinos
    Inventors: Alan KOZIKOWSKI, Sida SHEN, Joel BERGMAN, Irina GAISINA
  • SMALL MOLECULES INHIBITORS OF RAD51
    Publication number: 20190083491
    Abstract: Embodiments concern methods and small molecule compositions for selectively inhibiting RAD51-mediated D-loop formation while preserving RAD51's ability to form nucleoprotein filaments. The selective RAD51 D-loop formation activity inhibitors DNA repair while minimizing replication-associated toxicity in normal tissue.
    Type: Application
    Filed: March 2, 2017
    Publication date: March 21, 2019
    Inventors: Philip Connell, Wei Lv, Brian Budke, Alan Kozikowski
  • HDAC Inhibitors and Therapeutic Methods Using the Same
    Publication number: 20190023670
    Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed.
    Type: Application
    Filed: August 31, 2016
    Publication date: January 24, 2019
    Inventors: Alan Kozikowski, Irina Gaisina
  • CYCLOPROPYLMETHANAMINES AS SELECTIVE 5-HT(2C) RECEPTOR AGONISTS
    Publication number: 20180265453
    Abstract: Disclosed are 2-phenyl-cyclopropylmethanamines which are selective 5-HT(2C) receptor agonists and are used in the treatments of diseases and conditions wherein modulation of 5-HT(2C) receptors provides a benefit, such as obesity and psychiatric disorders.
    Type: Application
    Filed: January 27, 2016
    Publication date: September 20, 2018
    Inventors: Alan Kozikowski, Jianjun Cheng
  • Selective histone deactylase 6 inhibitors
    Patent number: 9956192
    Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: May 1, 2018
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Board of Trustees of The University of Illinois
    Inventors: Eduardo M. Sotomayor, Joel Bergman, Alan Kozikowski, Karrune Veeraprasert Woan, Alejandro V. Villagra
  • INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS
    Publication number: 20170044100
    Abstract: The present invention provides novel indoleamide compounds for treating tuberculosis, including drug-resistant M-tuberculosis, compositions comprising the indoleamides and methods of using the indoleamides in conjunction with other biologically active agents for the treatment of tuberculosis in a subject in need thereof.
    Type: Application
    Filed: April 22, 2015
    Publication date: February 16, 2017
    Inventors: William R. Bishai, Shichun Lun, Haidan Guo, Alan Kozikowski, Oluseye Onajole, Jozef Stec
  • SELECTIVE HISTONE DEACTYLASE 6 INHIBITORS
    Publication number: 20170035710
    Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.
    Type: Application
    Filed: August 8, 2016
    Publication date: February 9, 2017
    Inventors: Eduardo M. Sotomayor, Joel Bergman, Alan Kozikowski, Karrune Veeraprasert Woan, Alejandro V. Villagra
  • Selective histone deactylase 6 inhibitors
    Patent number: 9409858
    Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: August 9, 2016
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Board of Trustees of the University of Illinois
    Inventors: Eduardo M. Sotomayor, Joel Bergman, Alan Kozikowski, Karrune Veeraprasert Woan, Alejandro V. Villagra
  • HDAC inhibitors and therapeutic methods using the same
    Patent number: 9249087
    Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: February 2, 2016
    Assignees: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Alan Kozikowski, Jay H. Kalin, Kyle V. Butler, Joel Bergman, Wayne W. Hancock
  • HDAC inhibitors and therapeutic methods using the same
    Patent number: RE47009
    Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: August 28, 2018
    Assignees: THE CHILDREN'S HOSPITAL OF PHILADELPHIA, THE TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Alan Kozikowski, Jay Hans Kalin, Kyle Vincent Butler, Joel Bergman, Wayne W. Hancock